Andrew Schiermeier, EVP, Development and Corporate Strategy at Intellia Therapeutics, Inc. (NTLA), bought 7,500 shares at $16.00 ($118K) on 2019-03-06, disclosed to the SEC on 2019-03-12.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.50 | 4,250 | $66K | 55.9% |
| 2 | $16.00 | 3,250 | $52K | 44.1% |
| Total | $15.72 avg | 7,500 | $118K | 100% |